Antipsychotic Drugs Flashcards
1
Q
chlorpromazine
A
- first generation antipsychotic
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
2
Q
fluphenazine
A
- first generation antipsychotic
- available as LAIA
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
3
Q
perphenazine
A
- first generation antipsychotic
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
4
Q
thioridazine
A
- first generation antipsychotic
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
5
Q
trifluoperazine
A
- first generation antipsychotic
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
6
Q
haloperidol
A
- first generation antipsychotic
- available as LAIA
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
7
Q
loxapine
A
- first generation antipsychotic
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
8
Q
molindone
A
- first generation antipsychotic
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
9
Q
pimozide
A
- first generation antipsychotic
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
10
Q
thiothixene
A
- first generation antipsychotic
- block D2, 5-ht, muscarinic, α1, and H1 receptors
- risk of EPS, and hyperprolactinemia
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
11
Q
iloperodone
A
- second generation antipsychotic
- block 5-HT2A and D2 receptors
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
12
Q
lurasidone
A
- second generation antipsychotic
- block 5-HT2A and D2 receptors
- ALSO a partial 5HT-1A agonist
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
13
Q
paliperidone
A
- second generation antipsychotic (metabolite of risperidone)
- available as LAIA
- block 5-HT2A and D2 receptors
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
14
Q
risperidone
A
- second generation antipsychotic
- available as LAIA
- block 5-HT2A and D2 receptors
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
15
Q
ziprasidone
A
- second generation antipsychotic
- block 5-HT2A and D2 receptors
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
16
Q
aripiprazole
A
- second generation antipsychotic
- available as LAIA
- partial agonist of 5-HT1A and D1 receptors
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
17
Q
brexpiprazole
A
- second generation antipsychotic
- partial agonist of 5-HT1A and D1 receptors
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
18
Q
cariprazine
A
- second generation antipsychotic
- block 5-HT2A and D2 receptors AND partial agonist of 5-HT1A and D1 receptors
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
19
Q
lumateperone
A
- second generation antipsychotic
- multiple receptor agonism
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
20
Q
asenapine
A
- second generation antipsychotic
- multiple receptor agonism
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
21
Q
clozapine
A
- second generation antipsychotic
- multiple receptor agonism
- risk of AGRANULOCYTOSIS, NMS, weight gain, metabolic syndrome, QT prolongation, stroke
- used for treatment resistant psychosis or multiple suicide attempts
22
Q
olanzapine
A
- second generation antipsychotic
- available as LAIA
- multiple receptor agonism
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
23
Q
quetipine
A
- second generation antipsychotic
- multiple receptor agonism
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
24
Q
pimavanserine
A
- second generation antipsychotic
- used for PARKINSONS PSYCHOSIS
- risk of NMS, weight gain, metabolic syndrome, QT prolongation, stroke
25
Q
valbenazine
A
- selective VMAT2 inhibitor
- treatment of tardive dyskinesia side effect
26
Q
deutetrabenazine
A
- selective VMAT2 inhibitor
- treatment of tardive dyskinesia side effect
